FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner FDA Schedules July 2026 PCAC Review of BPC 157, TB 500, MOTs C, KPV, Semax, Epitalon, DSIP PeptideRundown Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand